Apperloo EM, Cherney DZ, Kuhlman AB, Mann JF, Rasmussen S, Rossing P, Tuttle KR, Vrhnjak B, Heerspink HJ (2025)
Publication Type: Journal article
Publication year: 2025
Book Volume: 40
Pages Range: 352-359
Journal Issue: 2
DOI: 10.1093/ndt/gfae150
Background. This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status in people with type 2 diabetes and high cardiovascular risk. Methods. Pooled SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes) and PIONEER 6 (A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes) data were analyzed for change in eGFR slope by baseline hemoglobin A1c (HbA
APA:
Apperloo, E.M., Cherney, D.Z., Kuhlman, A.B., Mann, J.F., Rasmussen, S., Rossing, P.,... Heerspink, H.J. (2025). Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6. Nephrology Dialysis Transplantation, 40(2), 352-359. https://doi.org/10.1093/ndt/gfae150
MLA:
Apperloo, Ellen M., et al. "Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6." Nephrology Dialysis Transplantation 40.2 (2025): 352-359.
BibTeX: Download